Early beta blocker metoprolol tested in heart attack patients in intensive care
Tests metoprolol or a placebo pill in adults with heart attack.
Plain-language title generated from the registry record
Registry title: Early Beta Blocker Administration in STEMI Patients With SCAI B Status
Key facts
- Where
- Tel Aviv, IsraelSee the site
Where in Israel
- Tel-Aviv Sourasky Medical CenterTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Trial code
- NCT06967194
- Record updated
- 28 May 2025
- Original description
This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.Read full original descriptionShow less
Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status
This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.
When patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.
During the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.
The main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.
Inclusion: Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization; Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output >0.5 mL/kg/hour); Age 18 years or older; Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.
Exclusion: Bradycardia (heart rate <60 beats per minute); Known hypersensitivity to metoprolol; Pregnancy; Inability to provide informed consent; Evidence of pulmonary edema; PR interval >240 milliseconds; Second- or third-degree atrioventricular (AV) block; Active asthma.